kaal:position:2026-07-31-4941

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug. should be assessed against Kaal's source-bound claim that Even if regulators could obtain the depth of information needed for anticipatory rulemaking, acting on venture capital signals risks wasting scarce regulatory resources, because venture capital funds make many investments that do not succeed and companies still incubating may raise no clear regulatory issues. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

anticipatory regulatory action based on venture capital data alone
portfolio companies still in incubation
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.

Scholarly basis

kaal:claim:2808132-047
Wulf A. Kaal, Erik P.M. Vermeulen, How to Regulate Disruptive Innovation - From Facts to Data (2016). SSRN: https://ssrn.com/abstract=2808132
Source PDF sha256: 3515f2317ed9c1d33ae55d70467cdf1f6c4e350065ea6a887d5d7619599ad7d2

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2132
Mapping ambiguous: true

Topics

innovationdynamic-regulation

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0020 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: 525d8a1337ea4debfa57327bedabb6777ef56836fc00af09f3f1cb642dd6b1e0
curl -s https://wulfkaal.github.io/positions/2026-07-31-4941.md | sha256sum